Amneal Net Income From Continuing Ops from 2010 to 2026
| AMRX Stock | USD 14.50 0.10 0.68% |
Net Loss | First Reported 2016-12-31 | Previous Quarter 35.6 M | Current Value 18.1 M | Quarterly Volatility 105.4 M |
Check Amneal Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amneal Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 164.4 M, Interest Expense of 312.3 M or Selling General Administrative of 296.8 M, as well as many indicators such as Price To Sales Ratio of 0.96, Dividend Yield of 0.0728 or Days Sales Outstanding of 132. Amneal financial statements analysis is a perfect complement when working with Amneal Pharmaceuticals Valuation or Volatility modules.
Amneal | Net Income From Continuing Ops | Build AI portfolio with Amneal Stock |
The evolution of Net Income From Continuing Ops for Amneal Pharmaceuticals Class provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Amneal Pharmaceuticals compares to historical norms and industry peers.
Latest Amneal Pharmaceuticals' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Amneal Pharmaceuticals Class over the last few years. It is Amneal Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amneal Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Amneal Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 12,664,978 | |
| Coefficient Of Variation | 1,707 | |
| Mean Deviation | 164,772,967 | |
| Median | 68,578,000 | |
| Standard Deviation | 216,232,930 | |
| Sample Variance | 46756.7T | |
| Range | 813M | |
| R-Value | (0.54) | |
| Mean Square Error | 35073.4T | |
| R-Squared | 0.30 | |
| Significance | 0.02 | |
| Slope | (23,326,641) | |
| Total Sum of Squares | 748106.9T |
Amneal Net Income From Continuing Ops History
About Amneal Pharmaceuticals Financial Statements
Amneal Pharmaceuticals investors use historical fundamental indicators, such as Amneal Pharmaceuticals' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Amneal Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -66.5 M | -63.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Amneal Stock Analysis
When running Amneal Pharmaceuticals' price analysis, check to measure Amneal Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals is operating at the current time. Most of Amneal Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals' price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.